|
|
Blood, 1 November 2003, Vol. 102, No. 9, pp. 3354-3362.
Prepublished online as a Blood First Edition Paper on July 10, 2003; DOI 10.1182/blood-2003-03-0970.
Previous Article | Table of Contents | Next Article 
NEOPLASIA
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels
Niels W. C. J. van de Donk,
Marloes M. J. Kamphuis,
Berris van Kessel,
Henk M. Lokhorst, and
Andries C. Bloem
From the Departments of Immunology and Hematology, University Medical Center Utrecht, The Netherlands.
HMG-CoA reductase is the rate-limiting enzyme of the mevalonate pathway leading to the formation of cholesterol and isoprenoids such as farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP). The inhibition of HMG-CoA reductase by lovastatin induced apoptosis in plasma cell lines and tumor cells from patients with multiple myeloma. Here we show that cotreatment with mevalonate or geranylgeranyl moieties, but not farnesyl groups, rescued myeloma cells from lovastatin-induced apoptosis. In addition, the inhibition of geranylgeranylation by specific inhibition of geranylgeranyl transferase I (GGTase I) induced the apoptosis of myeloma cells. Apoptosis triggered by the inhibition of geranylgeranylation was associated with reduction of Mcl-1 protein expression, collapse of the mitochondrial transmembrane potential, expression of the mitochondrial membrane protein 7A6, cytochrome c release from mitochondria into the cytosol, and stimulation of caspase-3 activity. These results imply that protein geranylgeranylation is critical for regulating myeloma tumor cell survival, possibly through regulating Mcl-1 expression. Our results show that pharmacologic agents such as lovastatin or GGTase inhibitors may be useful in the treatment of multiple myeloma.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. J. Roelofs, C. M. Edwards, R. G. G. Russell, F. H. Ebetino, M. J. Rogers, and P. A. Hulley
Apomine Enhances the Antitumor Effects of Lovastatin on Myeloma Cells by Down-Regulating 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase
J. Pharmacol. Exp. Ther.,
July 1, 2007;
322(1):
228 - 235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. W.-L. Wong, J. W. Clendening, A. Martirosyan, P. C. Boutros, C. Bros, F. Khosravi, I. Jurisica, A. K. Stewart, P. L. Bergsagel, and L. Z. Penn
Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
Mol. Cancer Ther.,
June 1, 2007;
6(6):
1886 - 1897.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Dai, P. Khanna, S. Chen, X.-Y. Pei, P. Dent, and S. Grant
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation
Blood,
May 15, 2007;
109(10):
4415 - 4423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Muto, M. Hori, Y. Sasaki, A. Saitoh, I. Yasuda, T. Maekawa, T. Uchida, K. Asakura, T. Nakazato, T. Kaneda, et al.
Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor
Mol. Cancer Ther.,
March 1, 2007;
6(3):
987 - 994.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Trudel, A. K. Stewart, Z. Li, Y. Shu, S.-B. Liang, Y. Trieu, D. Reece, J. Paterson, D. Wang, and X.-Y. Wen
The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan
Clin. Cancer Res.,
January 15, 2007;
13(2):
621 - 629.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Yacoub, W. Hawkins, D. Hanna, H. Young, M. A. Park, M. Grant, J. D. Roberts, D. T. Curiel, P. B. Fisher, K. Valerie, et al.
Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment
Mol. Pharmacol.,
January 1, 2007;
71(1):
259 - 275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E Hothersall, C McSharry, and N C Thomson
Potential therapeutic role for statins in respiratory disease.
Thorax,
August 1, 2006;
61(8):
729 - 734.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S.-L. Liang, H. Liu, and A. Zhou
Lovastatin-Induced Apoptosis in Macrophages through the Rac1/Cdc42/JNK Pathway
J. Immunol.,
July 1, 2006;
177(1):
651 - 656.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Fortuny, S. de Sanjose, N. Becker, M. Maynadie, P. L. Cocco, A. Staines, L. Foretova, M. Vornanen, P. Brennan, A. Nieters, et al.
Statin Use and Risk of Lymphoid Neoplasms: Results from the European Case-Control Study EPILYMPH.
Cancer Epidemiol. Biomarkers Prev.,
May 1, 2006;
15(5):
921 - 925.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. N. Hamadmad, M. K. Henry, and R. J. Hohl
Erythropoietin Receptor Signal Transduction Requires Protein Geranylgeranylation
J. Pharmacol. Exp. Ther.,
January 1, 2006;
316(1):
403 - 409.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gomez-Benito, I. Marzo, A. Anel, and J. Naval
Farnesyltransferase Inhibitor BMS-214662 Induces Apoptosis in Myeloma Cells through PUMA Up-Regulation, Bax and Bak Activation, and Mcl-1 Elimination
Mol. Pharmacol.,
June 1, 2005;
67(6):
1991 - 1998.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Cafforio, F. Dammacco, A. Gernone, and F. Silvestris
Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells
Carcinogenesis,
May 1, 2005;
26(5):
883 - 891.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. W.C.J. van de Donk, H. M. Lokhorst, E. H.J. Nijhuis, M. M.J. Kamphuis, and A. C. Bloem
Geranylgeranylated Proteins are Involved in the Regulation of Myeloma Cell Growth
Clin. Cancer Res.,
January 15, 2005;
11(2):
429 - 439.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Bi, M. Baudry, J. Liu, Y. Yao, L. Fu, F. Brucher, and G. Lynch
Inhibition of Geranylgeranylation Mediates the Effects of 3-Hydroxy-3-methylglutaryl (HMG)-CoA Reductase Inhibitors on Microglia
J. Biol. Chem.,
November 12, 2004;
279(46):
48238 - 48245.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Wu, W. W.-L. Wong, F. Khosravi, M. D. Minden, and L. Z. Penn
Blocking the Raf/MEK/ERK Pathway Sensitizes Acute Myelogenous Leukemia Cells to Lovastatin-Induced Apoptosis
Cancer Res.,
September 15, 2004;
64(18):
6461 - 6468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Grant
Reducing cholesterol and overcoming drug resistance
Blood,
September 15, 2004;
104(6):
1598 - 1599.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Schmidmaier, P. Baumann, M. Simsek, F. Dayyani, B. Emmerich, and G. Meinhardt
The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase
Blood,
September 15, 2004;
104(6):
1825 - 1832.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. K. Pulfer and R. C. Murphy
Formation of Biologically Active Oxysterols during Ozonolysis of Cholesterol Present in Lung Surfactant
J. Biol. Chem.,
June 18, 2004;
279(25):
26331 - 26338.
[Abstract]
[Full Text]
[PDF]
|
 |
|
| |